Pharmacological Modulation of Myeloid-derived Suppressor Cells to Dampen Inflammation

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Sep 16

PMID 36110844

Authors

Chiel van Geffen

Constantin Heiss

Astrid Deissler

Saeed Kolahian

Affiliations

Soon will be listed here.

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous cell population with potent suppressive and regulative properties. MDSCs' strong immunosuppressive potential creates new possibilities to treat chronic inflammation and autoimmune diseases or induce tolerance towards transplantation. Here, we summarize and critically discuss different pharmacological approaches which modulate the generation, activation, and recruitment of MDSCs and , and their potential role in future immunosuppressive therapy.

Citing Articles

Myeloid-derived suppressor cells in influenza virus-induced asthma exacerbation.

van Geffen C, Lange T, Kolahian S Front Immunol. 2024; 15:1342497.

PMID: 38694499 PMC: 11061804. DOI: 10.3389/fimmu.2024.1342497.

The effect of adoptive transferring myeloid-derived suppressor cells in ventilator-induced lung injury mice.

Shan F, Tang F, Liu Y, Han X, Wu W, Tang Y Heliyon. 2024; 10(3):e25595.

PMID: 38356581 PMC: 10865327. DOI: 10.1016/j.heliyon.2024.e25595.

Naphthaleneoxypropargyl-Containing Piperazine as a Regulator of Effector Immune Cell Populations upon an Aseptic Inflammation.

Yu V, Sycheva Y, Kairanbayeva G, Dembitsky V, Balabekova M, Tokusheva A Molecules. 2023; 28(20).

PMID: 37894502 PMC: 10608911. DOI: 10.3390/molecules28207023.

Modulation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Natural Products.

Calderon J, Prieto K, Lasso P, Fiorentino S, Barreto A Arch Immunol Ther Exp (Warsz). 2023; 71(1):17.

PMID: 37410164 PMC: 10326112. DOI: 10.1007/s00005-023-00681-0.

Local and Systemic Injections of Human Cord Blood Myeloid-Derived Suppressor Cells to Prevent Graft Rejection in Corneal Transplantation.

Lee J, Sohn H, Kim C, Kim T, Lee H Biomedicines. 2022; 10(12).

PMID: 36551981 PMC: 9776015. DOI: 10.3390/biomedicines10123223.

References

Holmgaard R, Zamarin D, Li Y, Gasmi B, Munn D, Allison J . Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Rep. 2015; 13(2):412-24. PMC: 5013825. DOI: 10.1016/j.celrep.2015.08.077. View

Davenport A, Hyndman K, Dhaun N, Southan C, Kohan D, Pollock J . Endothelin. Pharmacol Rev. 2016; 68(2):357-418. PMC: 4815360. DOI: 10.1124/pr.115.011833. View

Pi R, Yang Y, Hu X, Li H, Shi H, Liu Y . Dual mTORC1/2 inhibitor AZD2014 diminishes myeloid-derived suppressor cells accumulation in ovarian cancer and delays tumor growth. Cancer Lett. 2021; 523:72-81. DOI: 10.1016/j.canlet.2021.09.017. View

Poschke I, Mougiakakos D, Hansson J, Masucci G, Kiessling R . Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010; 70(11):4335-45. DOI: 10.1158/0008-5472.CAN-09-3767. View

Ye C, Geng Z, Dominguez D, Chen S, Fan J, Qin L . Targeting Ornithine Decarboxylase by α-Difluoromethylornithine Inhibits Tumor Growth by Impairing Myeloid-Derived Suppressor Cells. J Immunol. 2015; 196(2):915-23. PMC: 4707077. DOI: 10.4049/jimmunol.1500729. View

Chen H, van der Touw W, Wang Y, Kang K, Mai S, Zhang J . Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J Clin Invest. 2018; 128(12):5647-5662. PMC: 6264729. DOI: 10.1172/JCI97570. View

Sun R, Luo H, Su J, Di S, Zhou M, Shi B . Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice. Mol Ther. 2020; 29(1):60-74. PMC: 7791086. DOI: 10.1016/j.ymthe.2020.09.034. View

Atretkhany K, Nosenko M, Gogoleva V, Zvartsev R, Qin Z, Nedospasov S . TNF Neutralization Results in the Delay of Transplantable Tumor Growth and Reduced MDSC Accumulation. Front Immunol. 2016; 7:147. PMC: 4835443. DOI: 10.3389/fimmu.2016.00147. View

Schafer C, Wang Y, Hough K, Sawant A, Grant S, Thannickal V . Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. Oncotarget. 2016; 7(46):75407-75424. PMC: 5340181. DOI: 10.18632/oncotarget.12249. View

10.

Porta C, Consonni F, Morlacchi S, Sangaletti S, Bleve A, Totaro M . Tumor-Derived Prostaglandin E2 Promotes p50 NF-κB-Dependent Differentiation of Monocytic MDSCs. Cancer Res. 2020; 80(13):2874-2888. DOI: 10.1158/0008-5472.CAN-19-2843. View

11.

Ma Z, Xia Y, Hu C, Yu M, Yi H . Quercetin promotes the survival of granulocytic myeloid-derived suppressor cells via the ESR2/STAT3 signaling pathway. Biomed Pharmacother. 2020; 125:109922. DOI: 10.1016/j.biopha.2020.109922. View

12.

Gobbo J, Marcion G, Cordonnier M, Dias A, Pernet N, Hammann A . Restoring Anticancer Immune Response by Targeting Tumor-Derived Exosomes With a HSP70 Peptide Aptamer. J Natl Cancer Inst. 2015; 108(3. DOI: 10.1093/jnci/djv330. View

13.

Ye T, Yang F, Zhu Y, Li Y, Lei Q, Song X . Inhibition of Stat3 signaling pathway by nifuroxazide improves antitumor immunity and impairs colorectal carcinoma metastasis. Cell Death Dis. 2017; 8(1):e2534. PMC: 5386364. DOI: 10.1038/cddis.2016.452. View

14.

Zhang Y, Bi Y, Yang H, Chen X, Liu H, Lu Y . mTOR limits the recruitment of CD11b+Gr1+Ly6Chigh myeloid-derived suppressor cells in protecting against murine immunological hepatic injury. J Leukoc Biol. 2014; 95(6):961-70. DOI: 10.1189/jlb.0913473. View

15.

Wu J, Zhang R, Tang N, Gong Z, Zhou J, Chen Y . Dopamine inhibits the function of Gr-1+CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity. J Leukoc Biol. 2014; 97(1):191-200. PMC: 4377827. DOI: 10.1189/jlb.5A1113-626RR. View

16.

Shen X, Okwan-Duodu D, Blackwell W, Ong F, Janjulia T, Bernstein E . Myeloid expression of angiotensin-converting enzyme facilitates myeloid maturation and inhibits the development of myeloid-derived suppressor cells. Lab Invest. 2014; 94(5):536-44. PMC: 4221240. DOI: 10.1038/labinvest.2014.41. View

17.

Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos I, Taverna F . Blockade of Myeloid-Derived Suppressor Cell Expansion with All- Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy. Cancer Res. 2018; 78(12):3220-3232. DOI: 10.1158/0008-5472.CAN-17-3415. View

18.

Ghonim M, Ibba S, Tarhuni A, Errami Y, Luu H, Dean M . Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer. J Immunother Cancer. 2021; 9(1). PMC: 7839867. DOI: 10.1136/jitc-2020-001643. View

19.

Zhang C, Wang S, Li J, Zhang W, Zheng L, Yang C . The mTOR signal regulates myeloid-derived suppressor cells differentiation and immunosuppressive function in acute kidney injury. Cell Death Dis. 2017; 8(3):e2695. PMC: 5386577. DOI: 10.1038/cddis.2017.86. View

20.

Alshetaiwi H, Pervolarakis N, McIntyre L, Ma D, Nguyen Q, Rath J . Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020; 5(44). PMC: 7219211. DOI: 10.1126/sciimmunol.aay6017. View